- ROUNDTABLE: Pharmacy’s future in sync with technology
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Senate passes Drug Quality and Security Act
- FDA approves liquid form of Merck HIV drug Isentress for infants, small children
- EXPERT BLOG: Provider status for pharmacists — one way or another
NEWARK, Calif. — Drug maker Depomed has expanded the geographic scope of a license agreement it has with Merck for diabetes drugs, the company said.
The licensing agreement, which the two companies entered in July 2009, gives Merck a non-exclusive license and other rights to certain Depomed patents for extended-release metformin, while Depomed will receive "modest" royalties on net product sales of the drug Janumet XR (sitagliptin; metformin hydrochloride) in countries in which the licensed patents cover the product.
The territory covered by the license agreement is now worldwide, Depomed said.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.